STOCK TITAN

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced significant advancements in its clinical program for Namodenoson, targeting hepatocellular carcinoma (HCC). A pivotal Phase III study is now open for enrollment focusing on patients with advanced liver cancer. Notably, a CPB liver cancer patient remains cancer-free six years post-treatment with Namodenoson. Previous Phase II data indicated improved overall survival rates for CPB7 patients treated with Namodenoson compared to placebo. The FDA and EMA have granted Orphan Drug and Fast Track status for this drug.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma announced advancements in developing Piclidenoson, aimed at treating canine osteoarthritis, supported by its partner Vetbiolix. The canine osteoarthritis market is projected to reach $3 billion by 2028. Vetbiolix's recent studies indicate Piclidenoson has optimal safety and efficacy for upcoming European clinical trials, with a favorable safety profile established. If successful, this could lead to regulatory approval and significant revenues for Can-Fite. The drug could offer a superior alternative to current treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (CANF) reported financial results for the quarter ending September 30, 2022, indicating a 6.1% revenue decline to $0.61 million compared to 2021. R&D expenses dropped 21.3% to $5.31 million, primarily due to completing the Phase III Piclidenoson study. The net loss decreased to $7.15 million from $8.50 million, largely thanks to reduced expenses. Can-Fite also highlighted significant clinical developments, including the clearance of cancer in a patient treated with Namodenoson and the positive Phase III results for Piclidenoson in psoriasis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced positive results from the Phase III COMFORT study for its drug Piclidenoson, targeting psoriasis. The study showed significant efficacy, surpassing placebo and demonstrating a safety profile comparable to that of placebo and better tolerated than Otezla®. CEO Dr. Pnina Fishman will present the findings at the 6th Annual Dermatology Drug Development Summit in Boston on November 2, 2022. With over 400 adults assessed, the promising outcomes set the stage for an upcoming pivotal Phase III registration trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma has announced the initiation of a global pivotal Phase III study for Namodenoson, a treatment for advanced liver cancer, also known as hepatocellular carcinoma (HCC). A case report presented at the AASLD’s The Liver Meeting highlights a patient who achieved a complete response after five years of treatment. The pivotal study is open for patient enrollment in various countries, including Israel and the U.S. Namodenoson holds Orphan Drug and Fast Track Status in both the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma is advancing its Namodenoson liver drug candidate in a Phase IIb NASH study after a successful Phase IIa trial. CEO Dr. Pnina Fishman will present at the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022. NASH represents a significant market opportunity, expected to reach $35-$40 billion by 2025. The ongoing Phase IIb trial will evaluate Namodenoson’s efficacy against placebo in 140 subjects. Namodenoson has shown promise as a treatment for NASH and hepatocellular carcinoma, achieving Orphan Drug and Fast Track Designations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on September 24, 2022, at 7 p.m. ET. CEO Dr. Pnina Fishman will discuss key topics including the Company's Phase 3 trials for Psoriasis and Liver Cancer, and potential $100 million in milestone payments. Can-Fite is advancing therapies in inflammatory, cancer, and liver diseases, with drugs like Namodenoson and Piclidenoson showing promising results in clinical trials. The interview can be accessed in full on Can-Fite’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.64%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced positive results from the Phase III COMFORT™ study of its psoriasis treatment, Piclidenoson, presented by Dr. Kim Papp at the EADV Congress. The study met its primary endpoint, showing a statistically significant improvement over placebo (p=0.037) at 16 weeks. Piclidenoson demonstrated a safety profile comparable to placebo and better tolerability than Otezla®. The drug is set to progress into a pivotal Phase III registration trial for moderate to severe psoriasis and has shown promise for long-term treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) reported financial results for the quarter ending June 30, 2022, showcasing a strong balance sheet with $12.72 million in cash. Key developments include the approval of Namodenoson for compassionate use in Romania and the initiation of a pivotal Phase III study for liver cancer. The Phase III COMFORT trial for psoriasis successfully met its primary endpoint with Piclidenoson. Revenues reached $0.40 million, up 2.7%, while net loss declined to $4.62 million. The company plans to submit registration for Piclidenoson to FDA and EMA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
Rhea-AI Summary

Can-Fite BioPharma announced that its liver cancer drug Namodenoson has been approved for compassionate use in Romania, showing complete response in at least one patient. The Phase III pivotal study for advanced liver cancer is now open for patient enrollment in multiple countries, including Israel and the U.S. The FDA and EMA have provided regulatory support, and Namodenoson has Orphan Drug and Fast Track status. The liver cancer market is projected to reach $3.8 billion by 2027, reflecting a significant opportunity for Can-Fite.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.48 as of December 20, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 8.8M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

CANF Stock Data

8.84M
6.10M
10.5%
2.27%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan